Kaken Pharmaceutical Co., Ltd. (4521.T) Stock
Kaken Pharmaceutical Co., Ltd.

Company profile
Kaken Pharmaceutical reported revenue of 94.04 billion JPY for fiscal year 2025, and net income of 13.95 billion JPY. That is a net profit margin of 14.8% for fiscal year 2025. Its largest business segment, Pharmaceutical Industry, brought in 97% of segment revenue in fiscal year 2025. Our analysis of its filings shows revenue growing from 72.98 billion JPY in fiscal year 2023 to 94.04 billion JPY in fiscal year 2025, 13.5% a year on average. Kaken Pharmaceutical reports about 1,114 full-time employees.
What stands out
- Revenue rose 30.5% in fiscal year 2025, from 72.04 billion JPY in fiscal year 2024, after a fall of 1.3% the year before.
Figures from company filings; latest fiscal year ended March 31, 2025.
About Kaken Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins, that are used as fungicides; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001, which is in phase III clinical trial for the treatment of refractory vascular malformations; Seladelpar that is in phase III clinical trial for primary biliary cholangitis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Largest shareholders
- Kaken Pharmaceutical Co., Ltd.13.76%
- Japan Agricultural Cooperatives Group4.17%
- Mizuho Financial Group, Inc.3.34%
- Toray Industries, Inc.2.60%
- Kyorin Pharmaceutical Co., Ltd.1.93%
Share of the company, as of September 25, 2026
Leadership
- Hiroyuki Horiuchi — Chairman, President & Representative Director, 63
- Tomoyuki Koseki — Chief Officer of Marketing & Sales Division
- Mitsuru Watanuki — Chief Officer of R&D Division and Director, 61
- Keizo Kimura — Corporate Officer, Chief Officer of Production Division & Chief of Shizuoka Factory
- Tomohiro Takaya Ph.D. — General Manager of Legal Affairs & Intellectual Property Department
How much revenue does Kaken Pharmaceutical make?
Kaken Pharmaceutical reported 94.04 billion JPY in revenue for fiscal year 2025, up 30.5% from 72.04 billion JPY in fiscal year 2024.
What is Kaken Pharmaceutical's largest business segment?
Pharmaceutical Industry, with 91.55 billion JPY or 97% of segment revenue in fiscal year 2025. Next: Real Estate (3%).
What companies are similar to Kaken Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Nxera Pharma Co., Ltd. (4565.T), Towa Pharmaceutical Co., Ltd. (4553.T), Kissei Pharmaceutical Co., Ltd. (4547.T), Katakura Industries Co.,Ltd. (3001.T).
How has Kaken Pharmaceutical's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 74.98 billion JPY; FY2022, 76.03 billion JPY; FY2023, 72.98 billion JPY; FY2024, 72.04 billion JPY; FY2025, 94.04 billion JPY.
Company Information
Data as of .
How to cite: DataPorium, “Kaken Pharmaceutical Co., Ltd. (4521.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4521.T